Valo Health terminated the $2.8bn deal to go public via a SPAC merger with Khosla Ventures Acquisition.

Valo Health, a biotechnology company, terminated the $2.8bn deal to go public via a SPAC merger with Khosla Ventures Acquisition, a special purposes acquisition company. "We formed KVSA to merge with companies that are impactful to the world as we recently did with KVSB when we merged with Nextdoor. Valo Health is a strong company and we wish them continued success as they move forward on a very solid plan. We will continue to look for other high-impact targets across a range of industries to deliver maximum shareholder value," Samir Kaul, Khosla Ventures Founding Partner and Managing Director.